Absci (ABSI) Projected to Post Earnings on Wednesday

Key Points

• Absci is set to announce its Q2 2025 earnings on August 13, expecting to report a loss of ($0.19) per share and revenue of $1.39 million.
• Recent analysts' ratings for Absci reflect mixed sentiments, with price targets ranging from $6.40 to $9.00 and a consensus rating of "Moderate Buy".
• Insider Andreas Busch purchased 50,000 shares, increasing his ownership in Absci by 18.03%, indicating confidence in the company's potential.

Absci (NASDAQ:ABSI - Get Free Report) is projected to issue its Q2 2025 quarterly earnings data after the market closes on Wednesday, August 13th. Analysts expect the company to announce earnings of ($0.19) per share and revenue of $1.39 million for the quarter.

Absci (NASDAQ:ABSI - Get Free Report) last released its earnings results on Tuesday, May 13th. The company reported ($0.21) EPS for the quarter, topping analysts' consensus estimates of ($0.23) by $0.02. Absci had a negative return on equity of 53.69% and a negative net margin of 2,232.13%. The firm had revenue of $1.18 million for the quarter, compared to analysts' expectations of $1.07 million. On average, analysts expect Absci to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Absci Stock Performance

Shares of ABSI stock traded up $0.01 during trading hours on Thursday, reaching $2.92. The company had a trading volume of 3,895,984 shares, compared to its average volume of 6,591,245. Absci has a one year low of $2.01 and a one year high of $6.33. The firm has a market cap of $372.48 million, a PE ratio of -3.17 and a beta of 2.02. The business has a fifty day moving average price of $2.86 and a 200-day moving average price of $3.19.

Insider Activity

In other news, insider Andreas Busch acquired 50,000 shares of the stock in a transaction that occurred on Monday, July 28th. The shares were bought at an average cost of $3.04 per share, for a total transaction of $152,000.00. Following the acquisition, the insider owned 327,264 shares in the company, valued at approximately $994,882.56. This represents a 18.03% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 10.49% of the stock is owned by company insiders.

Institutional Investors Weigh In On Absci

A number of large investors have recently modified their holdings of the business. AQR Capital Management LLC increased its position in shares of Absci by 279.4% during the 1st quarter. AQR Capital Management LLC now owns 55,538 shares of the company's stock worth $139,000 after purchasing an additional 40,901 shares during the last quarter. Goldman Sachs Group Inc. increased its stake in Absci by 17.5% in the first quarter. Goldman Sachs Group Inc. now owns 314,858 shares of the company's stock valued at $790,000 after purchasing an additional 46,975 shares during the last quarter. Finally, Woodline Partners LP lifted its position in Absci by 32.9% in the first quarter. Woodline Partners LP now owns 1,391,245 shares of the company's stock valued at $3,492,000 after acquiring an additional 344,270 shares during the last quarter. Hedge funds and other institutional investors own 52.05% of the company's stock.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on ABSI shares. Needham & Company LLC reissued a "buy" rating and set a $9.00 price target on shares of Absci in a report on Wednesday, May 14th. KeyCorp raised their price target on Absci from $5.00 to $9.00 and gave the stock an "overweight" rating in a research report on Wednesday, April 16th. Morgan Stanley decreased their price target on Absci from $7.00 to $6.40 and set an "overweight" rating for the company in a research note on Monday, July 28th. Finally, Wall Street Zen upgraded Absci from a "sell" rating to a "hold" rating in a report on Saturday, August 2nd. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company's stock. Based on data from MarketBeat, Absci currently has a consensus rating of "Moderate Buy" and a consensus price target of $8.28.

About Absci

Absci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company in the United States. The company combines AI with scalable wet lab technologies to create biologics for patients. Its integrated drug creation platform is designed to improve upon traditional biologic drug discovery by using AI to simultaneously optimize multiple drug characteristics that may be important to development and therapeutic benefit.